$30.35
4.76% day before yesterday
Nasdaq, May 16, 10:19 pm CET
ISIN
US05370A1088
Symbol
RNA
Sector
Industry

Avidity Biosciences Inc Stock price

$30.35
+4.59 17.82% 1M
-11.00 26.60% 6M
+1.27 4.37% YTD
+1.63 5.68% 1Y
+16.75 123.16% 3Y
+1.85 6.49% 5Y
+1.85 6.49% 10Y
Nasdaq, Closing price Fri, May 16 2025
+1.38 4.76%
ISIN
US05370A1088
Symbol
RNA
Sector
Industry

Key metrics

Market capitalization $3.66b
Enterprise Value $2.28b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 255.81
P/S ratio (TTM) P/S ratio 409.67
P/B ratio (TTM) P/B ratio 2.75
Revenue growth (TTM) Revenue growth -17.87%
Revenue (TTM) Revenue $8.93m
EBIT (operating result TTM) EBIT $-433.27m
Free Cash Flow (TTM) Free Cash Flow $-365.22m
Cash position $1.38b
EPS (TTM) EPS $-3.01
P/E forward negative
P/S forward 581.84
EV/Sales forward 363.32
Short interest 13.05%
Show more

Is Avidity Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,790 stocks worldwide.

Avidity Biosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Avidity Biosciences Inc forecast:

14x Buy
100%

Analyst Opinions

14 Analysts have issued a Avidity Biosciences Inc forecast:

Buy
100%

Financial data from Avidity Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
8.93 8.93
18% 18%
100%
- Direct Costs 2.92 2.92
24% 24%
33%
6.01 6.01
15% 15%
67%
- Selling and Administrative Expenses 100 100
107% 107%
1,121%
- Research and Development Expense 336 336
60% 60%
3,765%
-430 -430
71% 71%
-4,819%
- Depreciation and Amortization 2.92 2.92
24% 24%
33%
EBIT (Operating Income) EBIT -433 -433
70% 70%
-4,852%
Net Profit -369 -369
61% 61%
-4,135%

In millions USD.

Don't miss a Thing! We will send you all news about Avidity Biosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Avidity Biosciences Inc Stock News

Neutral
PRNewsWire
10 days ago
On track to deliver key regulatory updates for del-brax and topline data from dose escalation cohorts in the FORTITUDE™ trial in the second quarter Positive topline del-zota data further supports first BLA submission at year end 2025 – continues to highlight reproducibility and consistency across three late-stage clinical trials for DMD44, DM1 and FSHD  Executing on global commercial infrastruc...
Neutral
PRNewsWire
12 days ago
SAN DIEGO , May 6, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will participate in a fireside chat during the following investor conference: Bank of America Securities 2025 Health Care Conference on Tues...
Neutral
PRNewsWire
27 days ago
SAN DIEGO , April 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on April 20, 2025, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate...
More Avidity Biosciences Inc News

Company Profile

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) designed to treat a range of serious diseases. The company's lead product candidate is AOC 1001 for treatment of myotonic dystrophy type 1; and four other muscle programs, which focus on the treatment of muscle atrophy, duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. It utilizes its proprietary AOC platform to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and target underlying genetic drivers of diseases. The company also has development programs that focuses on immune and other cell types. Avidity Biosciences, Inc. was founded in 2012 and is based in La Jolla, California.

Head office United States
CEO Sarah Boyce
Employees 391
Founded 2012
Website www.aviditybiosciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today